France where omeprazole co-prescribing decreased in [2008][2009]. The most frequently prescribed PPI in combination with clopidogrel was omeprazole in all three countries (58% in the UK, 36% in France and 65% in Germany) The second most frequently used PPI was lansoprazole in the UK (36%), pantoprazole in Germany (21%) and esomeprazole in France (28%). The proportion of clopidogrel patients who were co-prescribed lansoprazole was 36% in the UK and only 11% in France and 2% in Germany. CONCLUSIONS: Overall prescribing of PPIs with clopidogrel after ACS is common in the UK, France and Germany. Since the publication of the OCLA study in 2008 no decrease in concurrent prescribing of clopidogrel and omeprazole was observed except in France. Revisions of national guidelines and the clopidogrel label in 2009 may further affect prescribing of PPIs, and especially omeprazole, with clopidogrel in the future. OBJECTIVES: A previous study indicated that increasing nurse staffi ng levels in Belgian general cardiac postoperative nursing units was associated with lower mortality rates. The aim of this study is to conduct a cost-effectiveness analysis of increasing nurse staffi ng levels to the level of the 75 th percentile in Belgian general cardiac postoperative nursing units from a hospital perspective. METHODS: The intervention was an increase in the number of nursing hours per patient day to the 75 th percentile for nursing units staffed below that level. The comparator was a "do nothing" alternative. Data on nurse staffi ng levels were extracted from the Belgian Nursing Minimum Data set and data on in-hospital mortality from the Belgian Hospital Discharge Database. The number of life-years gained was calculated by multiplying the number of avoided deaths by the life expectancy of patients having a coronary artery bypass graft and patients having heart valve procedures. To this effect, survival rates were derived from the literature. National cost estimates for the year 2007 were used. Results were expressed in the form of the additional costs per avoided death and the additional costs per life-year gained. RESULTS: The costs of increasing nurse staffi ng levels to the 75 th percentile in Belgian general cardiac postoperative nursing units amounted to c1,211,022. Such nurse staffi ng levels would avoid an estimated number of 45.9 (95% CI: 22.0-69.4) patient deaths per year and generate 458.86 (95% CI: 219.93-693.79) life-years gained annually. This corresponds with incremental cost-effectiveness ratios of c26,372 per avoided death and c2,639 per life-year gained. Sensitivity analyses indicated that the incremental cost-effectiveness ratio was robust to changes in input parameters. CONCLUSIONS: Increasing nurse staffi ng levels appears to be a costeffective intervention as compared to other cardiovascular interventions. OBJECTIVES: Health services research is an expanding fi eld of interest for recently introduced medical technologies. Complementing effi cacy results with effectiveness data illustrates the clinical contribution of a new technology in the real-life setting. With effectiveness results being relatively stable over time, the change in reimbursement and price decreases have a substantial impact on initial cost-effectiveness considerations. The three-year GERSHWIN study (GERman Stent Health outcomes WIthin Normal practice) was designed to determine long-term clinical outcome and economic consequences of Sirolimus-eluting stents (SES) versus bare-metal stents BMS in the treatment of CAD from a societal prospective. Economic analysis resulted in an ICER of c29,868 per avoided major adverse coronary events (MACE) based on 2003 to 2005 prices. Due to substantial price reductions, a remodelling with current prices would increase applicability of results by decision-makers. METHODS: Complete intention-to-treat study data were valued and analyzed with 2009 prices for the main cost drivers (hospital case rate, incremental stent cost and generic clopidogrel price). Sensitivity analyses were conducted to evaluate the robustness of the results and included a low-and high-cost scenario. RESULTS: Initial hospitalization costs were c1157 higher per patient receiving SES, driven primarily by the incremental acquisition cost for SES compared BMS. Follow-up direct costs were similar in both groups of patients, however the indirect costs in SES patients were signifi cantly lower. Overall 36-month MACE-related costs were c283 not signifi cantly higher in the SES group (p = 0.62). The ICER based on 2009 cost data resulted in c5320 per MACE avoided. Variation of incremental SES prices between c650 and c750 showed no signifi cant impact. CONCLUSIONS: Incorporating updated cost data can drastically change the ICER generated from health services research projects. Modelling with current cost data is an essential contribution for iterative cost-benefi t assessment procedures. OBJECTIVES: Current European Society of Cardiology Guidelines recommend dual antiplatelet therapy for 12 months for all patients with acute coronary syndrome (ACS). The variations in antiplatelet treatment patterns at 6 months following hospital discharge were assessed in patients with unstable angina (UA), non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation MI (STEMI) undergoing percutaneous intervention (PCI). METHODS: A prospective, observational registry of 11 European countries grouped into 6 clusters recruited acute coronary syndrome (ACS) patients undergoing PCI from 2008-2009. Interventional cardiologists collected data from ACS events up to hospital discharge, and primary care physicians and cardiologists collected 6-month data. RESULTS: Of 3042 eligible patients at baseline, 2964 patients (97%) had 6 month data; 51% of patients presented with STEMI and 49% with UA/NSTEMI. The median age was 62 yrs. At 6 months following hospital discharge, the percentage of UA/NSTEMI and STEMI patients using clopidogrel, respectively, was 70% and 40% in the Czech Republic, 84% and 89% in Germany, 98% and 99% in Greece, 78% and 81% in the Nordic countries, 93% and 94% in Austria and Hungary, and 81% and 88% in Belgium and the The Netherlands. The percentage of UA/NSTEMI and STEMI patients taking aspirin, respectively, was 98% and 99% in the Czech Republic, 89% and 90% in Germany, 97% and 100% in Greece, 95% and 93% in the Nordic countries, 94% and 96% in Austria and Hungary, and 91% and 94% in Belgium and the The Netherlands. CONCLUSIONS: Use of clopidogrel varied considerably between European countries at 6 months after discharge, whereas the majority (≥90%) of patients continued to use aspirin. Results suggest that both physician and patient education on continuing dual antiplatelet therapy may be needed. OBJECTIVES: This analysis aims to explore management of acute coronary syndromes (ACS) from acute event to hospital discharge in Germany, and to measure Quality of Life (QoL) at discharge. METHODS: This 12-month international prospective, observational study recruited ACS patients undergoing percutaneous coronary intervention (PCI), April 2008-March 2009, capturing practice patterns, resource use and QoL. RESULTS: 500 ACS-PCI patients (out of the 508 recruited) were eligible: median age 63 yrs (IQR 53-72), median weight 82 kg (IQR 74-92), 23% female, 24% Type II diabetics, and 27% prior myocardial infarction (MI). Index diagnosis was: unstable angina or non-ST-elevation MI (UA/NSTEMI)-53% and ST-elevation MI (STEMI)-47%. Almost all patients (96%) received stents: 68% bare metal stents (BMS) only, 29% drug eluting stents (DES) only and 3% both. Time from start of ACS symptoms to PCI was 3 days or less in 91% of UA/NSTEMI patients and 1 day or less in 97% of STEMI patients. Oral antiplatelet medications with loading dose (LD) used: aspirin-86% and clopidogrel-93%. Clopidogrel LD was administered in PCV136
PCV129 TELEHEALTH-EARLY EVALUATION FINDINGS
Beale S 1 , Tatlock S 1 , Wheeler K 2 , Ryan J 2 1 University of York, York, North Yorkshire, UK; 2 NHS, York, North Yorkshire, UK OBJECTIVES: NHS North Yorkshire and York commissioned York Health Economics Consortium to carry out an evaluation of their recent Telehealth pilot involving patients with long-term conditions. The fi ndings from the evaluation will be used to inform plans for the further rollout of Telehealth in North Yorkshire. METHODS: Three approaches were employed: a questionnaire was used to obtain details about the Telehealth experiences of users and their carers; Case Managers and Community Matrons with Telehealth patients on their caseloads were interviewed about referral criteria and the impact of Telehealth on their role and patient care; Health care resource use data were analyzed. Some caution should be used when generalizing fi ndings due to the small sample size and the specifi c characteristics of pilot Telehealth recipients. RESULTS: Forty-eight questionnaires were handed out and twenty returned (42%). Overall, respondents were happy with Telehealth (90%). Results showed that the installation process had been smooth (75%); individuals had received suffi cient tuition (95%); they were confi dent using the equipment (95%); and were happy with the service received from the monitoring centre (95%). Telehealth gave users peace of mind and helped them to manage their own health condition. However, a number of users had experienced technical issues (during installation and when taking daily measurements). Although there had been some teething problems, mainly in relation to the installation process and the monitoring system, clinicians were broadly supportive of Telehealth. There was a repeated view that individual patient characteristics needed to be taken into account when identifying patients who would benefi t from Telehealth. The impact of Telehealth on health care resource use was diffi cult to determine within the eight month timescale of the pilot. CONCLUSIONS: Telehealth gives users peace of mind and helps them manage their health; however, its impact on health care resource use is still unclear.
PCV130 PRACTICE PATTERNS AND QUALITY OF LIFE IN ACUTE CORONARY SYNDROME PATIENTS IN 2008-2009: BASELINE RESULTS FOR AUSTRIA FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY II (APTOR II)
Ammer M 1 , Paget MA 2 , Hronkova M 3 , Norrbacka K 4 , Eber B 1 1 Klinikum der Kreuzschwestern Wels, Wels, Austria; 2 Lilly France S.A., Suresnes Cedex, France; 3 Eli Lilly & Company, Vienna, Austria; 4 Eli Lilly & Company, Vantaa, Finland OBJECTIVES: This analysis aims to explore management of acute coronary syndromes (ACS) from acute event to hospital discharge in Austria, and to measure Quality of Life (QoL) at discharge. METHODS: This 12-month international, prospective, observational study recruited ACS patients in selected hospitals undergoing percutaneous coronary intervention (PCI), April 2008-March 2009, capturing practice patterns, resource use and QoL. RESULTS: A total of 148 ACS-PCI patients (out of the 152 recruited) were eligible: median age 60 yrs (IQR 51-69), median weight 80 kg (IQR 70-89), 20% female, 28% Type II diabetics, and 17% prior myocardial infarction (MI). Index diagnosis was: unstable angina or non-ST-elevation MI (UA/ NSTEMI)-44% and ST-elevation MI (STEMI)-56%. Almost all patients (96%) received stents: 28% bare metal stents only, 70% drug eluting stents only and 2% both. Time from start of ACS symptoms to PCI was ≤3 days in 86% of UA/NSTEMI patients and ≤1 day in 98% of STEMI patients. Oral antiplatelet medications with loading dose (LD) used: aspirin-97% and clopidogrel-91%. Clopidogrel LD was administered in the ambulance-9%, previous hospital-10%, emergency room-41%, CCU or ICU-31%, catheterization lab-5%, or other ward-5%. LD was administered between 6 hours before to 6 hours after PCI in 82% of cases. The fi rst clopidogrel LD was 600 mg in 85% and 300 mg in 10% of cases and in-hospital maintenance dose was 75 mg in 97%. At time of hospital discharge, 97% of the discharged patients were prescribed clopidogrel (discharge dose 75 mg for all patients except one). QoL in discharged patients was good: median EQ-5D health state index at 1.00 (IQR 0.81-1.00). CONCLUSIONS: These real life data refl ect treatment patterns among ACS patients managed by PCI in selected hospitals in Austria in 2008-2009. Timing and place of loading of antiplatelet agents differ. The QoL of patients at discharge was high.
PCV131 AN INTERNATIONAL COMPARISON OF DUAL ANTIPLATELET USE BY STENT TYPE AT 6 MONTHS FOLLOWING HOSPITAL DISCHARGE AFTER ACUTE CORONARY SYNDROME: RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY II (APTOR-II)
Pavlides G 1 , Coufal Z 2 , Mohacsi A 3 , James S 4 , Zeymer U 5 , Paget MA 6 , Goedicke J 7 , Norrbacka K 8 , Berkenboom G 9 1 Onassis Cardiac Surgery Center, Kallithca, Greece; 2 Bata's Regional Hospital, Zlin, Czech Republic; 3 Hungarian Institute of Cardiology, Budapest, Hungary; 4 Uppsala University Hospital, Uppsala, Sweden; 5 Herzzentrum Ludwigshafen, Ludwigshafen, Germany; 6 Lilly France S.A., Suresnes Cedex, France; 7 Eli Lilly & Company, Hamburg, Germany; 8 Eli Lilly & Company, Vantaa, Finland; 9 U.L.B Erasme Hospital Brussels, Brussels, Belgium OBJECTIVES: Current European Society of Cardiology Guidelines recommend dual antiplatelet therapy for 12 months for patients with acute coronary syndrome (ACS); however, reimbursement for antiplatelet therapy differs by EU country and is dependent upon the use of bare metal (BMS) or drug-eluting (DES) stents during percutaneous coronary intervention (PCI). Dual antiplatelet (clopidogrel + aspirin) treatment patterns were assessed at 6 months following hospital discharge for patients who received only BMS and for patients with at least 1 DES. METHODS: A prospective, observational registry of 11 European countries grouped into 6 clusters recruited ACS patients undergoing PCI from 2008-2009. Interventional cardiologists collected data from ACS events up to hospital discharge, and primary care physicians and cardiologists collected 6-month data. RESULTS: Of 3042 eligible patients at baseline, 2964 (97%) had 6-month data, of which 2842 (96%) received a stent at index PCI. The percentage of patients with at least 1 DES was 17% in the Czech Republic, 31% in Germany, 33% in Austria-Hungary, 33% in Belgium-The Netherlands, 37% in the Nordic countries, and 81% in Greece. The percentage of patients taking dual antiplatelet therapy at hospital discharge ranged from 93% in Belgium-The Netherlands to 100% in Greece for BMS only and from 93% in Belgium-The Netherlands to 100% in Czech Republic for patients with DES. At 6 months, the percentage of patients taking dual antiplatelet therapy ranged from 45% in Czech Republic to 97% in Greece for BMS-only patients and from 83% in Belgium-The Netherlands to 97% in Greece for patients with DES. Aspirin use ranged from 89% to 100% across the countries and type of stent. CONCLUSIONS: Use of DES versus BMS varied among the European countries. In patients with BMS, there was marked variability with clopidogrel use at 6 months; whereas, in patients with DES, clopidogrel was used more frequently and with less variability. the ambulance-7%, previous hospital-8%, emergency room-32%, CCU or ICU-23%, catheterization lab-25%, other ward 5%. LD was administered just before or direct after PCI in 79% of cases. The clopidogrel LD was 600 mg in 68% and 300 mg in 24% of cases and in-hospital maintenance dose (MD) was 75 mg in 98%. At time of hospital discharge, 92% of discharged patients were receiving clopidogrel (discharge dose 75 mg in all cases). QoL in discharged patients was good: median EQ-5D health state index at 0.85 (IQR 0.73-1.00). CONCLUSIONS: These real life data refl ect treatment patterns among ACS patients managed by PCI in Germany in 2008-2009. Timing and place of antiplatelet loading differ between patients. The QoL of patients at discharge was high.
PCV134
THERAPEUTIC VERSUS ACTUAL MARKET SHARES FOR STATINS Gorevski E, Bian B, Kelton C, Boone J, Guo JJ University of Cincinnati, Cincinnati, OH, USA OBJECTIVES: This study estimated market shares for six statins based on 1) the literature-determined lipid-lowering potential of the drugs, and 2) the distribution of U.S. adults depending on the amount of lipid-lowering they required. Estimated market shares were compared with actual market shares. METHODS: Two panels (1999-2000 and 2001-2002) from the National Health and Nutrition Examination Survey (NHANES) provided interview, demographic, and laboratory data for 3324 people >20 years of age who were not taking a statin. In accordance with the ATP III Guidelines, coronary heart disease (CHD) and CHD-risk-equivalent events including diabetes, other risk factors such as smoking and high blood pressure, and Framingham scores to obtain 10-year risk estimates were identifi ed and calculated, respectively for each person, along with percentage LDL-C lowering required to reach his or her LDL-C goal. Depending on the amount of lowering needed and on whether the individual had a liver condition, hence, enhanced risk of rhabdomyolysis, a particular statin or particular statins with equal probabilities were assigned to the individual; e.g., a person without a liver condition requiring 50% lowering of LDL-C would be assigned rosuvastatin or atorvastatin, each with probability = 0.5. RESULTS: Of 1643 men surveyed, 57.88% were in the lowest-risk group (0-1 risk factors); 14.36% were in the highest-risk group (CHD or CHD-risk-equivalent). For the 1681 women, these percentages were 73.11% and 11.30%, respectively. Of people needing a statin, 73.74% needed LDL-C lowering by <25%; only 1.16% required LDL-C lowering of >60%. Therapeutic market shares were estimated at 20.11% (rosuvastatin); 18.94% (atorvastatin); 17.89% (simvastatin); 16.96% (lovastatin); 13.05% (fl uvastatin); and 13.05% (pravastatin). CONCLUSIONS: Actual market shares are signifi cantly different from market shares based on lipid-lowering considerations. Explanations include direct-to-consumer advertising; varying pricing strategies; and clinical trials for additional indications and subpopulations conducted only by the market leaders.
PCV135 CREATING AN EFFICIENT HOSPITAL PAYMENT SYSTEM
Baser O 1 , Gust C 2
